We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Delivers Long-Anticipated Guidance on Diversity Action Plans
FDA Delivers Long-Anticipated Guidance on Diversity Action Plans
The FDA has published overdue draft guidance on developing diversity action plans for clinical trials, moving the agency a step closer to the statutory mandate that all phase 3 trials include such plans.